Pfizer Inc. $PFE Stake Lowered by Swiss Life Asset Management Ltd

Swiss Life Asset Management Ltd trimmed its stake in shares of Pfizer Inc. (NYSE:PFE) by 2.2% during the third quarter, Holdings Channel reports. The firm owned 5,702,699 shares of the biopharmaceutical company’s stock after selling 126,498 shares during the period. Pfizer comprises about 0.8% of Swiss Life Asset Management Ltd’s holdings, making the stock its 21st largest position. Swiss Life Asset Management Ltd’s holdings in Pfizer were worth $145,305,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the stock. State Street Corp grew its stake in Pfizer by 0.9% during the 3rd quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company’s stock worth $7,620,747,000 after buying an additional 2,786,098 shares during the last quarter. Norges Bank bought a new stake in Pfizer in the second quarter valued at $2,270,157,000. Northern Trust Corp boosted its holdings in shares of Pfizer by 1.4% during the third quarter. Northern Trust Corp now owns 64,019,807 shares of the biopharmaceutical company’s stock valued at $1,631,225,000 after acquiring an additional 869,175 shares during the period. Fisher Asset Management LLC boosted its holdings in shares of Pfizer by 1.9% during the third quarter. Fisher Asset Management LLC now owns 49,288,054 shares of the biopharmaceutical company’s stock valued at $1,255,860,000 after acquiring an additional 897,786 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Pfizer by 2.4% during the second quarter. Charles Schwab Investment Management Inc. now owns 49,165,032 shares of the biopharmaceutical company’s stock worth $1,191,760,000 after acquiring an additional 1,135,457 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

PFE has been the topic of several recent research reports. UBS Group started coverage on shares of Pfizer in a research report on Tuesday, January 6th. They issued a “neutral” rating and a $25.00 price objective on the stock. Citigroup started coverage on shares of Pfizer in a research report on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 target price for the company. Barclays assumed coverage on shares of Pfizer in a research note on Thursday, February 19th. They issued an “underweight” rating and a $25.00 price target on the stock. Daiwa Securities Group cut Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price target on the stock. in a report on Thursday, February 12th. Finally, TD Cowen reissued a “hold” rating on shares of Pfizer in a report on Tuesday, December 30th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have issued a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $28.14.

Pfizer Stock Performance

PFE stock opened at $27.33 on Thursday. The company has a market capitalization of $155.38 billion, a P/E ratio of 20.09 and a beta of 0.47. The company has a 50-day simple moving average of $26.61 and a 200 day simple moving average of $25.57. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.94. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm had revenue of $17.56 billion for the quarter, compared to analysts’ expectations of $16.93 billion. During the same quarter last year, the company earned $0.63 EPS. Pfizer’s quarterly revenue was down 1.2% on a year-over-year basis. Sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Positive Phase 3 topline — Pfizer reported positive topline results from the Phase 3 TALAPRO-3 study showing TALZENNA (talazoparib) plus XTANDI (enzalutamide) significantly improved radiographic progression‑free survival in HRR‑mutated metastatic castration‑sensitive prostate cancer, a meaningful late‑stage win that could expand a high‑value oncology franchise. TALAPRO-3 Topline
• Positive Sentiment: Mid‑stage breast cancer data supports pipeline — Pfizer’s Phase 2 FOURLIGHT‑1 trial of atirmociclib met its primary endpoint in second‑line HR+/HER2‑ metastatic breast cancer, cutting risk of progression and strengthening Pfizer’s bid to follow on from CDK4/6 leaders (Ibrance, etc.). This readout is being positioned as a key oncology catalyst. Atirmociclib Phase 2 Results
• Positive Sentiment: Analyst upgrade and price‑target lift — HSBC raised its price target to $32 and moved to a buy rating, citing upside to Pfizer’s valuation; that upgrade has drawn investor attention and provided near‑term support. HSBC Upgrade
• Neutral Sentiment: Early‑stage liver program advanced — Pfizer updated progress on a Phase 1 PF‑07328948 liver study, which modestly supports the pipeline but is an early, lower‑visibility catalyst. PF‑07328948 Liver Study
• Neutral Sentiment: Public commentary and investor interest — Media/columnist coverage (including Jim Cramer) and various valuation pieces have increased attention on PFE, driving trading volume but not a clear directional catalyst. Cramer & Media Coverage
• Negative Sentiment: Program trimming: early‑stage melanoma study ended — Pfizer discontinued an early‑stage melanoma study (PF‑08046031), which trims one oncology bet and tempers the otherwise bullish pipeline narrative. Melanoma Study Stop
• Negative Sentiment: Industry pricing scrutiny — A Reuters/analysis piece on TrumpRx highlights continued political scrutiny of U.S. drug prices; broader policy and pricing headlines can pressure large pharma multiples and investor sentiment for companies like Pfizer. TrumpRx Pricing Analysis

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.